Results 221 to 230 of about 38,538 (308)

Editorial: Bispecific antibodies and their conjugates in solid tumors and hematological malignancies. [PDF]

Front Immunol
Püsküllüoğlu M, Pacholczak-Madej R.
europepmc   +1 more source

Repurpose an FDA‐Approved Antibody Using DARPin‐Scaffolded Bridge Protein

Chemistry–Methods, Volume 6, Issue 5, May 2026.
The cell line and scalable upstream/downstream process development needed for every new monoclonal antibody are both highly expensive and time‐consuming, significantly increasing the cost of new antibody therapeutics. By contrast, the production of many synthetic binders can be accomplished rapidly and with lower production costs.
Michael Woolley, Joshua D. Bryant, Samuel Vrana, Karuppiah Chockalingam, Zhilei Chen   +4 more
wiley   +1 more source

A Generalized Minimal PBPK-PD Model of Bispecific Antibodies: Case Studies and Applications in Drug Development. [PDF]

CPT Pharmacometrics Syst Pharmacol
Spinosa P, Joslyn L, Ramanujan S, Gadkar K, Hosseini I.   +4 more
europepmc   +1 more source

In vivo CAR therapies: Turning the patient into their own CAR factory

HemaSphere, Volume 10, Issue 5, May 2026.
Abstract Over the past decade, ex vivo autologous chimeric antigen receptor (CAR)‐T‐cell therapies have reshaped the treatment of B‐cell malignancies. Despite their remarkable clinical efficacy, their application remains limited by complex manufacturing processes, demanding logistics, long turnaround times, and substantial costs. In vivo CAR approaches
François Vilcot, Carole‐Anne Brugère, Jaime Fuentealba, Roch Houot   +3 more
wiley   +1 more source

Landscape of T-cell engagers in solid tumors. [PDF]

Oncologist
Garcia-Lorenzo E, Dorta M, Doger B, Pedregal M, Moreno V.   +4 more
europepmc   +1 more source

Outcomes and salvage strategies for large B‐cell lymphoma progressing after second‐line CAR T‐cell therapy: A DESCAR‐T study from the LYSA group

HemaSphere, Volume 10, Issue 5, May 2026.
Abstract Relapse after chimeric antigen receptor (CAR) T‐cell therapy in large B‐cell lymphoma (LBCL) is associated with a dismal prognosis. Although Phase 3 trials have established CAR T‐cells as standard second‐line (2L) therapy, outcomes and optimal management after relapse in this setting remain unknown because no real‐world data are currently ...
Pierre Sesques, Guillaume Manson, Guillaume Cartron, François‐Xavier Gros, Franck Morschhauser, Cristina Castilla‐Llorente, Gabriel Brisou, Pierre Bories, Catherine Thieblemont, Laurianne Drieu La Rochelle, Benoit Tessoulin, Axel André, Cedric Rossi, Jérôme Paillassa, Stephanie Guidez, Antoine Capes, Laura Herbreteau, Sylvain Choquet, Jacques‐Olivier Bay, Adrien Chauchet, Laure Lebras, Fabien Claves, Julie Abraham, Jean‐Valère Malfuson, Marie‐Thérèse Rubio, Justine Decroocq, Luc‐Matthieu Fornecker, Gandhi Damaj, Ludovic Fouillet, Magalie Joris, Michael Loschi, Olivier Hermine, Hadia Hafirassou, Emelie Van Zele, Vivien Dupont, Steven Le Gouill, Roch Houot, Vincent Camus   +37 more
wiley   +1 more source

Engineered neutrophil engagers overcome IgA limitations and reprogram resting neutrophils for cancer immunotherapy. [PDF]

J Biol Eng
Lee J, Han G, Kyung M, Lee S, Kim TW, Jung ST.   +5 more
europepmc   +1 more source

The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non–Secretory Relapse—A Retrospective Cohort Study

Hematological Oncology, Volume 44, Issue 3, May 2026.
ABSTRACT Oligo‐secretory and non‐secretory MM present a clinical challenge due to the difficulties in initial diagnosis, response to treatment assessment, and relapse detection. They are excluded from most clinical trials, which typically require measurable disease.
Iuliana Vaxman, Itai Zamir, Inbar Cohen, Gil Fridberg, Tamir Shragai, Svetlana Trestman, Tomer Ziv Baran, Efrat Luttwak, Ronit Shmuel, Natan Melamed, Shai Levy, Irit Avivi, Pia Raanani, Angela Dispenzieri, Morie A. Gertz, Yael C. Cohen   +15 more
wiley   +1 more source

Breakthroughs of bispecific antibodies therapy in multiple myeloma: latest updates from 2025 ASH. [PDF]

Biomark Res
Zhao B, Bu Q, Chen AL, Zhu HH.
europepmc   +1 more source

Nonclassical MHC‐I Molecules: Emerging Therapeutic Targets in Next‐Generation Immunotherapy

MedComm, Volume 7, Issue 5, May 2026.
Immunotherapies dependent on classical MHC‐I molecules face significant challenges, including extreme polymorphism and frequent downregulation in pathological conditions. This review discusses how nonclassical MHC‐I molecules (HLA‐E, HLA‐F, HLA‐G, CD1, MR1) may potentially circumvent these limitations through restricted genetic diversity, stable ...
Wanlin He, Andrew J. McMichael
wiley   +1 more source